诚意药业上半年净利润同比增长47.03%

Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. reported significant growth in its 2025 semi-annual results, with a focus on marine economy and health products as key growth drivers [2] Financial Performance - The company achieved operating revenue of 417 million yuan, a year-on-year increase of 17.11% [2] - Net profit attributable to shareholders reached 112 million yuan, reflecting a 47.03% increase compared to the same period last year [2] - The net profit excluding non-recurring gains and losses was 111 million yuan, up 54.21% year-on-year [2] Business Strategy - Chengyi Pharmaceutical is committed to the dual-driven strategy of pharmaceuticals and health products, aligning with national initiatives to develop the marine economy and marine biomedicine [2] - In the pharmaceutical sector, the company focuses on a full industry chain approach, increasing R&D investment to enhance competitive advantages in clinical treatment areas such as bone and joint, cardiovascular, anti-infection, and nervous system [2] Product Development - The company prioritized key profitable products for consistency evaluation and new product development, successfully passing consistency evaluation for two specifications of sodium cytidine injection [2] - New products such as mercaptopurine tablets have been approved, and the raw material for dobutamine hydrochloride has been filed successfully [2] - As of the date of the interim report, the company has obtained a drug registration certificate for palivizumab injection [2] Market Focus - In the health product sector, the company strategically focuses on marine biomedicine and the silver economy, seizing opportunities from consumption upgrades and increased health awareness [2]